Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy

Terminated

Conditions: Urinary Bladder, Overactive

Interventions: Other: Toviaz(fesoterodine) plus educational materials
Other: Toviaz(fesoterodine) without educational materials

First Posted Date: 2010-03-24

Last Posted Date: 2013-03-07

Lead Sponsor: Pfizer

Target Recruit Count: 781

Registration Number: NCT01091519

A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.

Phase 1

Completed

Conditions: Pharmacokinetic
Phase 1
Multiple Dose
Safety
Toleration

Interventions: Drug: UK-396,082
Drug: placebo

First Posted Date: 2010-03-24

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01091532

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Phase 2

Completed

Conditions: Metastatic Progressive Castration-resistant Prostate Cancer

Interventions: Drug: Enzalutamide

First Posted Date: 2010-03-23

Last Posted Date: 2018-10-23

Lead Sponsor: Pfizer

Target Recruit Count: 60

Registration Number: NCT01091103

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

PF-00489791 For The Treatment Of Raynaud's

Phase 2

Completed

Conditions: Raynaud's Disease
Peripheral Vascular Disease

Interventions: Drug: PF-00489791

First Posted Date: 2010-03-22

Last Posted Date: 2018-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 243

Registration Number: NCT01090492

Locations: 🇺🇸
Stanford Hospital and Outpatient Center, Redwood City, California, United States
🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

and more 52 locations

Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets

Completed

Conditions: Alzheimer Disease

Interventions: Other: No intervention

First Posted Date: 2010-03-18

Last Posted Date: 2011-04-28

Lead Sponsor: Pfizer

Target Recruit Count: 628

Registration Number: NCT01089582

Locations: 🇬🇷
University Hospital of Alexandroupolis Dimokritio, Alexandroupolis, Thrace, Greece
🇬🇷
General Hospital of Arta, Arta, Greece
🇬🇷
NIMITS (Geriatric Department), Athens, Greece

and more 26 locations

Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study

Phase 3

Terminated

Conditions: Arthritis
Pain
Osteoarthritis

Interventions: Biological: Placebo IV
Biological: Tanezumab SC
Biological: Tanezumab IV
Biological: Placebo SC

First Posted Date: 2010-03-18

Last Posted Date: 2021-05-05

Lead Sponsor: Pfizer

Target Recruit Count: 385

Registration Number: NCT01089725

Locations: 🇺🇸
Vaughn H. Mancha, Jr., MD, PC, Montgomery, Alabama, United States
🇺🇸
Novara Clinical Research, Mesa, Arizona, United States
🇺🇸
Redpoint Research, Phoenix, Arizona, United States

and more 84 locations

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: PF-03382792 0.5mg
Drug: PF-03382792 1.5 mg
Drug: PF-03382792 5 mg
Drug: PF-03382792 15 mg

First Posted Date: 2010-03-18

Last Posted Date: 2018-11-06

Lead Sponsor: Pfizer

Registration Number: NCT01089738

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

Phase 2

Terminated

Conditions: Diabetic Peripheral Neuropathy

Interventions: Biological: Tanezumab
Biological: placebo

First Posted Date: 2010-03-16

Last Posted Date: 2021-02-24

Lead Sponsor: Pfizer

Target Recruit Count: 73

Registration Number: NCT01087203

Locations: 🇺🇸
Alabama Orthopaedic Clinic, Mobile, Alabama, United States
🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸
Dedicated Clinical Research, Litchfield Park, Arizona, United States

and more 44 locations

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia

Completed

Conditions: Vaccines, Pneumococcal
Pneumonia, Pneumococcal

Interventions: Procedure: Urine sample collection

First Posted Date: 2010-03-15

Last Posted Date: 2012-03-15

Lead Sponsor: Pfizer

Target Recruit Count: 782

Registration Number: NCT01086397

Locations: 🇺🇸
University of South Alabama Division of Clinical Research, Mobile, Alabama, United States
🇺🇸
Sharpe-Grossmont Hospital, La Mesa, California, United States
🇺🇸
Tampa General Hospital, Tampa, Florida, United States

and more 10 locations

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

Not Applicable

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Donepezil
Drug: Placebo

First Posted Date: 2010-03-09

Last Posted Date: 2013-09-12

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT01082965

Locations: 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy